Molecular Therapy-Methods & Clinical Development

Article	Citations
Molecular earplugs to protect the inner ear	89
RNA-seq analysis of the human surfactant air-liquid interface culture reveals alveolar type II cell-like transcriptome	85
Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization	72
Protein phosphatase 2A anchoring disruptor gene therapy for familial dilated cardiomyopathy	64
Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia	61
Thank you to our 2024 reviewers	56
Preclinical evaluation of NG101, a potential AAV gene therapy for wet age-related macular degeneration	56
Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy	55
A blood-brain barrier-penetrant AAV gene therapy improves neurological function in symptomatic mucolipidosis IV mice	52
Identification of the role of SNARE proteins in rAAV vector production through interaction with the viral MAAP	52
Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model	50
First use of adeno-associated viruses in the human inner ear	49
Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates	49
Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration	48
Cell-penetrating peptides enhance the transduction of adeno-associated virus serotype 9 in the central nervous system	47
Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia	46
Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication	45
Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy	45
Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering	44
Exploring Human Plasma Proteomic Variations in Mucolipidosis Type IV	43
CRISPR-Cas9 correction of a nonsense mutation in LCA5 rescues lebercilin expression and localization in human retinal organoids	42
Unfolding of viral protein 1 N-termini facilitates genome ejection from recombinant adeno-associated virus serotype 8	42
Differential T cell immune responses to deamidated adeno-associated virus vector	40
Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution	40
Genetic surgery for a cystic fibrosis-causing splicing mutation	39

Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy	38
Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids	38
Circulating neurofilaments to track dorsal root ganglion toxicity risks with AAV-mediated gene therapy	37
The unknown impact of conditioning on HSC engraftment and clonal dynamics	35
Quantification of full and empty particles of adeno-associated virus vectors via a novel dual fluorescence-linked immunosorbent assay	35
A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies	35
Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells	35
Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells	34
Modulation of AAV transduction and integration targeting by topoisomerase poisons	33
An HPLC-SEC-based rapid quantification method for vesicular stomatitis virus particles to facilitate process development	33
Synergy between Lactobacillus murinus and anti-PcrV antibody delivered in the airways to boost protection against Pseudomonas aeruginosa	33
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia	30
Efficacy and muscle safety assessment of fukutin-related protein gene therapy	30
Evidence generation and reproducibility in cell and gene therapy research: A call to action	29
Applying a clinical lens to animal models of CAR-T cell therapies	29
An investigation of the immune epitopes of adeno-associated virus capsid-derived peptides among hemophilia patients	29
Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy	28
The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice	28
Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases	28
CRISPR-Cas9-mediated somatic correction of a one-base deletion in the Ugt1a gene ameliorates hyperbilirubinemia in Crigler-Najjar syndrome mice	28
Deconvolution of spatial sequencing provides accurate characterization of hESC-derived DA transplants in vivo	28
Determining recombinant AAV capsid extracellular and intracellular biodistribution by dual radioisotope labeling	28
Predicted deleterious variants in the human genome relevant to gene therapy with adeno-associated virus vectors	28
Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ-Ighmpb2	27
Development of novel lipoplex formulation methodologies to improve large-scale transient transfection for lentiviral vector manufacture	27
A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin	27
Inducible caspase 9-mediated suicide gene therapy using AAV6 vectors in a murine model of breast cancer	27
Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells	26
Nonviral delivery of nCas9 for “safe harbor” integration to treat MPS IVA	26
A combinatorial CRISPR-Cas12a attack on HIV DNA	26
Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β	25
Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD	25
Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A	25
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products	25
Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy	25
Biodistribution and safety of a single rAAV3B-AAT vector for silencing and replacement of alpha-1 antitrypsin in Cynomolgus macaques	24
A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats	24
Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics	24
Confirmatory detection of neutralizing antibodies to AAV gene therapy using a cell-based transduction inhibition assay	24
Manufacturing DNA in E. coli yields higher-fidelity DNA than in vitro enzymatic synthesis	23
Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications	23
AAV8BP2 and AAV8 transduce the mammalian cochlear lateral wall and endolymphatic sac with high efficiency	23
Research progress of mosquito-borne virus mRNA vaccines	22
Bringing base editing to the clinic: The next generation of genome editors	22
Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis	22
Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CAR NK cells	21
In-depth comparison of Anc80L65 and AAV9 retinal targeting and characterization of cross-reactivity to multiple AAV serotypes in humans	21
In vitro and in vivo expansion of CD33/HBG promoter-edited HSPCs with Mylotarg	21
Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model	21
Full-length ATP7B reconstituted through protein trans-splicing corrects Wilson disease in mice	21

A novel approach to quantitate biodistribution and transduction of adeno-associated virus gene therapy using radiolabeled AAV vectors in mice	21
Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8	20
Toward lentiviral vectors for antiangiogenic ocular gene therapy	20
Optimizing AAV2/6 microglial targeting identified enhanced efficiency in the photoreceptor degenerative environment	20
Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing	20
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation	20
Toward effective hematopoietic stem cell gene therapies: Optimized conditioning regimen and stem cell source in harmony	20
Comparison of analytical techniques to quantitate the capsid content of adeno-associated viral vectors	20
Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping	20
Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells	20
Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells	20
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease	19
Human amnionic progenitor cell secretome mitigates the consequence of traumatic optic neuropathy in a mouse model	19
Gene editing-based targeted integration for correction of Wiskott-Aldrich syndrome	19
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice	19
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity	19
Cell-penetrating peptides enhance the transduction of adeno-associated virus serotype 9 in the central nervous system	19
Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors	19
Universal ddPCR-based assay for the determination of lentivirus infectious titer and lenti-modified cell vector copy number	19
Non-canonical capsid engineering highlights new possibilities for AAV vectorology	19
Starburst amacrine cells amplify optogenetic visual restoration through gap junctions	19
Efficient and sustained FOXP3 locus editing in hematopoietic stem cells as a therapeutic approach for IPEX syndrome	19
Extracellular vesicles ameliorates sleep deprivation induced anxiety-like behavior and cognitive impairment in mice	18
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device	18
Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor	18
Targeted biallelic integration of an inducible Caspase 9 suicide gene in iPSCs for safer therapies	18
Assessment of genome packaging in AAVs using Orbitrap-based charge-detection mass spectrometry	18
Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles	18
Brain-targeted ex vivo lentiviral gene therapy: Implications for MPS and beyond	18
Assessment of adeno-associated virus purity by capillary electrophoresis-based western	18
Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6	18
Atelocollagen supports three-dimensional culture of human induced pluripotent stem cells	18
mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance	18
Induction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of T cell epitope usage or mouse strain background	18
Immunosuppression reduces rAAV2.5T neutralizing antibodies that limit efficacy following repeat dosing to ferret lungs	17
Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein	17
Improving cell-specific recombination using AAV vectors in the murine CNS by capsid and expression cassette optimization	17
It’s all about location: Targeting the right spot for Wiskott-Aldrich syndrome	17
Rationally engineered novel AAV capsids for intra-articular gene delivery	17
Gene therapy using an ortholog of human fragile X mental retardation protein partially rescues behavioral abnormalities and EEG activity	17
Molecular dynamics of genome editing with CRISPR-Cas9 and rAAV6 virus in human HSPCs to treat sickle cell disease	17
Lentiviral vector mediated gene therapy for type I Dent disease ameliorates Dent disease-like phenotypes for three months in ClC-5 null mice	17
Low endotoxin E. coli strain-derived plasmids reduce rAAV vector-mediated immune responses both in vitro and in vivo	17
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2	17
VikAD, a Vika site-specific recombinase-based system for efficient and scalable helper-dependent adenovirus production	17
Robust induction of TRMs by combinatorial nanoshells confers cross-strain sterilizing immunity against lethal influenza viruses	16
Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells	16
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients	16
Comparing the efficacy of γ- and electron-irradiation of PBMCs to promote secretion of paracrine, regenerative factors	16
Multiplex CRISPR/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations	16
Targeting the lung epithelium after intravenous delivery by directed evolution of underexplored sites on the AAV capsid	16
In vivo targeting of a variant causing vanishing white matter using CRISPR/Cas9	16
Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers	16
Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS	16
Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease	16
Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec	16
Transduction characteristics of alternative adeno-associated virus serotypes in the cat brain by intracisternal delivery	15
Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies	15
Engineered mesenchymal stromal cell therapy during human lung ex vivo lung perfusion is compromised by acidic lung microenvironment	15
A positive take on negative selection for CAR-T manufacturing	15
A clinically viable approach to restoring visual function using optogenetic gene therapy	15
Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model	15
A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR	15
Peptide-encoding gene transfer to modulate intracellular protein-protein interactions	15
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis	15
Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy	15
A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery	15
Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine	15
Persistent tailoring of MSC activation through genetic priming	15
Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells	14
Efficient generation of liver sinusoidal endothelial-like cells secreting coagulation factor VIII from human induced pluripotent stem cells	14
Engineering a highly durable adeno-associated virus receptor for analytical applications	14
Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice	14
Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL	14
Gene therapy for Friedreich ataxia: Too much, too little, or just right?	14
CRISPR-Cas9-mediated genome editing delivered by a single AAV9 vector inhibits HSV-1 reactivation in a latent rabbit keratitis model	14
Characterization and effective expansion of CD4−CD8− TCRαβ+ T cells from individuals living with type 1 diabetes	14
Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection	14
Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene	14
Insights in AAV-mediated antigen-specific immunity and a strategy for AAV vaccine dose reduction through AAV-extracellular vesicle association	14

Efficient autocrine and paracrine signaling explain the osteogenic superiority of transgenic BMP-2 over rhBMP-2	14
Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease	14
Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy	13
Packaging cells for lentiviral vectors generated using the cumate and coumermycin gene induction systems and nanowell single-cell cloning	13
AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life	13
PCR-based analytics of gene therapies using adeno-associated virus vectors: Considerations for cGMP method development	13
AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 Deficiency	13
DNA contamination within recombinant adeno-associated virus preparations correlates with decreased CD34+ cell clonogenic potential	13
Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs	13
Measurement solutions and standards for advanced therapy	13
Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy	13
Production of recombinant adeno-associated virus 5 using a novel self-attenuating adenovirus production platform	13
Deciphering key parameters enhancing lentiviral vector producer cells yields: Vector components copy number and expression	13
Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics	13
Exogenous expression of ATP8, a mitochondrial encoded protein, from the nucleus in vivo	13
High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography	13
From Puppies to adults: In vivo editing of hepatocytes in a canine model of glycogen storage disease type Ia	13
Can mitochondria brown the lower-limb adipocytes?	13
Perspectives of the Friedreich ataxia community on gene therapy clinical trials	13
Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine	13
Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy	13
Follistatin-like 1 promotes proliferation of matured human hypoxic iPSC-cardiomyocytes and is secreted by cardiac fibroblasts	13
An autonucleolytic suspension HEK293F host cell line for high-titer serum-free AAV5 and AAV9 production with reduced levels of DNA impurity	13
Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette	13
Rescue of myocytes and locomotion through AAV2/9-2YF intracisternal gene therapy in a rat model of creatine transporter deficiency	13
Voluntary wheel running complements microdystrophin gene therapy to improve muscle function in mdx mice	12
Evaluation of efficacy and safety of AAV8-ΔC4ATP7B gene therapy in a mutant mouse model of Wilson’s disease	12
Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters	12
Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys	12
Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models	12
CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa	12
Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets	12
mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model	12
miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1	12
Clinical holds for cell and gene therapy trials: Risks, impact, and lessons learned	12
In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2	12
B cell focused transient immune suppression protocol for efficient AAV readministration to the liver	12
Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma	12
An automated and high-throughput approach for enhanced precision of adenoviral titering	12
Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II	12
Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study	12
Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence	12
High throughput screening of novel AAV capsids identifies variants for transduction of adult NSCs within the subventricular zone	12
An improved medium formulation for efficient ex vivo gene editing, expansion and engraftment of hematopoietic stem and progenitor cells	11
Whole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia	11
Identification of a novel neutralization epitope in rhesus AAVs	11
Treatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathways	11
Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates	11
PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington’s disease	11
Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia	11
Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors	11
DNA-PK inhibition enhances gene editing efficiency in HSPCs for CRISPR-based treatment of X-linked hyper IgM syndrome	11
Analytical band centrifugation for the separation and quantification of empty and full AAV particles	11
The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs	11
Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth	11
Implementing a robust platform analytical procedure for measuring adeno-associated virus vector genome titer	11
Macrophage manufacturing and engineering with 5′-Cap1 and N1-methylpseudouridine-modified mRNA	11
A novel FOXP3 knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products	11
GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy	10
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper	10
Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages	10
Structural basis for the neurotropic AAV9 and the engineered AAVPHP.eB recognition with cellular receptors	10
Population-wide gene disruption in the murine lung epithelium via AAV-mediated delivery of CRISPR-Cas9 components	10
Semi-automated workflows to quantify AAV transduction in various brain areas and predict gene editing outcome for neurological disorders	10
An etanercept O-glycovariant with enhanced potency	10
Characterization of AAV vectors: A review of analytical techniques and critical quality attributes	10
Intravenous immunoglobulin prevents peripheral liver transduction of intrathecally delivered AAV vectors	10
NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform	10
Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy	10
Novel AAV variants with improved tropism for human Schwann cells	10
Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics	10
Toward a translational gene therapy for mucolipidosis IV	10
E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells	10
Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1	10
Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series	10
Embryo and fetal gene editing: Technical challenges and progress toward clinical applications	10
Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis	10
Immunocompromised Cas9 transgenic mice for rapid in vivo assessment of host factors involved in highly pathogenic virus infection	10
The ratio of nicotinic acid to nicotinamide as a microbial biomarker for assessing cell therapy product sterility	9
Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation	9
Prostaglandin E2 as transduction enhancer affects competitive engraftment of human hematopoietic stem and progenitor cells	9
Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets	9
Modifying immune responses to adeno-associated virus vectors by capsid engineering	9
Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities	9
Swapping the serotype: A novel helper-dependent adenoviral vector platform for in vivo HSC gene therapy	9
Prevention of early-onset cardiomyopathy in Dmd exon 52–54 deletion mice by CRISPR-Cas9-mediated exon skipping	9
A Sensitive Sample Preparation Pipeline for Adventitious Virus Detection Using Oxford Nanopore Sequencing	9
Development of a one-step RT-ddPCR method to determine the expression and potency of AAV vectors	9
A novel FOXP3 knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products	9
A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer	9
Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues	9
AAV-BDNF gene therapy ameliorates a hypothalamic neuroinflammatory signature in the Magel2-null model of Prader-Willi syndrome	9
Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output	9
Dual-AAV vector-mediated expression of MYO7A improves vestibular function in a mouse model of Usher syndrome 1B	9
AAV-mediated rescue of Eps8 expression in vivo restores hair-cell function in a mouse model of recessive deafness	9